These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31219038)

  • 1. Successful Treatment of Corticosteroid-Refractory Hypereosinophilia With Reslizumab.
    Coffey K; Fajt ML; Acho M; Gladwin M; Petrov AA
    J Investig Allergol Clin Immunol; 2019 Jun; 29(3):241-242. PubMed ID: 31219038
    [No Abstract]   [Full Text] [Related]  

  • 2. Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab.
    Buttgereit T; Bonnekoh H; Church MK; Bergmann KC; Siebenhaar F; Metz M
    J Dtsch Dermatol Ges; 2019 Nov; 17(11):1171-1172. PubMed ID: 31479567
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab.
    Kuruvilla M
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):670-671. PubMed ID: 29496465
    [No Abstract]   [Full Text] [Related]  

  • 4. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
    Schwartz LB; Sheikh J; Singh A
    Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood.
    Schwarz C; Müller T; Lau S; Parasher K; Staab D; Wahn U
    Pediatr Allergy Immunol; 2018 Feb; 29(1):28-33. PubMed ID: 28986919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reslizumab: Maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.
    Paton DM
    Drugs Today (Barc); 2016 Jun; 52(6):323-9. PubMed ID: 27458609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis.
    Manka LA; Guntur VP; Denson JL; Dunn RM; Dollin YT; Strand MJ; Wechsler ME
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):696-701.e1. PubMed ID: 33548468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L6. Eosinophilic granulomatosis with polyangiitis: future therapies.
    Moosig F
    Presse Med; 2013 Apr; 42(4 Pt 2):510-2. PubMed ID: 23453508
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of Hypereosinophilic Syndromes.
    Roufosse F
    Immunol Allergy Clin North Am; 2015 Aug; 35(3):561-75. PubMed ID: 26209900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal Manifestations of Hypereosinophilic Syndromes and Mast Cell Disorders: a Comprehensive Review.
    Nanagas VC; Kovalszki A
    Clin Rev Allergy Immunol; 2019 Oct; 57(2):194-212. PubMed ID: 30003499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypereosinophilic syndrome presenting as an unusual triad of eosinophilia, severe thrombocytopenia, and diffuse arterial thromboses, with good response to mepolizumab.
    Leon-Ferre RA; Weiler CR; Halfdanarson TR
    Clin Adv Hematol Oncol; 2013 May; 11(5):317-9. PubMed ID: 23880717
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical management of the hypereosinophilic syndromes.
    Cogan E; Roufosse F
    Expert Rev Hematol; 2012 Jun; 5(3):275-89; quiz 290. PubMed ID: 22780208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An unusual presentation of idiopathic hypereosinophilic syndrome.
    Thakral C
    Clin Adv Hematol Oncol; 2013 May; 11(5):320-1. PubMed ID: 23880718
    [No Abstract]   [Full Text] [Related]  

  • 14. Benralizumab in Severe and Refractory PDGFRA-Negative Hypereosinophilic Syndrome.
    Alen Coutinho I; Regateiro FS; Loureiro C; Todo-Bom A
    J Clin Immunol; 2021 Apr; 41(3):688-690. PubMed ID: 33394318
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug-induced hypereosinophilia related to tocilizumab therapy for rheumatoid arthritis.
    Morrisroe K; Wong M
    Rheumatology (Oxford); 2015 Nov; 54(11):2113-4. PubMed ID: 26224305
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting CCR4 with mogamulizumab in refractory CD3
    Ledoult E; Groh M; Meresse B; Dubois R; Trauet J; Toussaint E; Delbeke M; Hachulla E; Terriou L; De Masson A; Vasseur M; Labalette M; Launay D; Kahn JE; Lefevre G
    Haematologica; 2024 Jun; 109(6):1984-1988. PubMed ID: 38328856
    [No Abstract]   [Full Text] [Related]  

  • 17. Ocular involvement in idiopathic hypereosinophilic syndrome: a rare finding.
    Balaskas K; Wyss P; Guex-Crosier Y
    Klin Monbl Augenheilkd; 2012 Apr; 229(4):437-8. PubMed ID: 22496024
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel therapies for hypereosinophilic syndromes.
    Antoniu SA
    Neth J Med; 2010 Aug; 68(1):304-10. PubMed ID: 20739727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Corticosteroid Treatment for Refractory Multivessel Vasospastic Coronary Angina with Hypereosinophilia.
    Takano T; Ozaki K; Tanaka K; Yanagawa T; Ozawa T; Minamino T
    Intern Med; 2018 Nov; 57(21):3111-3115. PubMed ID: 29877265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How I treat hypereosinophilic syndromes.
    Klion AD
    Blood; 2009 Oct; 114(18):3736-41. PubMed ID: 19692700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.